CVC Capital Partners leads consortium to Alvogen takeover
A group of investors led by European private equity fund CVC Capital Partners has acquired a controlling stake in Alvogen.
Singapore state Investment Company Temasek and Vatera Healthcare Partners are the other parties to the deal which is believed to have valued drug company Alvogen at $2bn.
Alvogen chief executive Robert Wessman will retain a significant stake and continue in his executive role.
Wessman said the company is one of the fastest growing generic pharmaceutical companies in the industry, and has moved from being a US business to a global player.
CVC partner Tomas Ekman said together with co-investors CVC is delighted to be working with Alvogen to continue its “extraordinary expansion.”